U.S. market Open. Closes in 5 hours 15 minutes

RSLS | ReShape Lifesciences Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 5.04 - 5.18
52 Week Range 4.60 - 34.22
Beta N/A
Implied Volatility N/A
IV Rank N/A
Day's Volume 1,383
Average Volume 226,111
Shares Outstanding 712,680
Market Cap 3,588,344
Sector Healthcare
Industry Medical - Devices
IPO Date 2016-10-06
Valuation
Profitability
Growth
Health
P/E Ratio 0.07
Forward P/E Ratio N/A
EPS 77.26
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 29
Country USA
Website RSLS
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.
RSLS's peers: BBLG, CODX, EYEG, HSDT, IINN, MYO, NAOV, NSPR, NURO, NUWE, SINT, RMED, TIVC, TLIS, TNON, INVO, HSCS, OPGN
*Chart delayed
Analyzing fundamentals for RSLS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is on medium level and Health is frighteningly weak. For more detailed analysis please see RSLS Fundamentals page.

Watching at RSLS technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on RSLS Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙